This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: and placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again press star and the number one. I would now like to turn the call over to Chad Keech, Chief Investment Officer. Please go ahead.
spk06: Thank you, operator, and welcome, everyone. We filed our earnings press release yesterday, and it is available on the investor relations section of our website at EnzymeGroup.net. A replay of this call will also be available on our website until 5 p.m. Pacific on Friday, November 24th, 2023. We want to remind any listeners that may be listening to a replay of this call that all the statements made are as of today, October 26th, 2023, and these statements have not been nor will be updated subsequent to today's call. Also, any forward-looking statements made today are based on management's current expectations, assumptions, and beliefs about our business and the environment in which we operate. These statements are subject to risks and uncertainties that could cause our actual results to materially differ from those expressed or implied on today's call. Listeners should not place under reliance on forward-looking statements and are encouraged to review our SEC filings for more complete discussion of factors that could impact our results. Except as required by federal securities laws, Ensign and its affiliates do not undertake to publicly update or revise any forward-looking statements where changes arise as a result of new information, future events, changing circumstances, or for any other reason. In addition, the Ensign Group Inc. is a holding company with no direct operating assets, employees, or revenues. Certain of our wholly owned independent subsidiaries, collectively referred to as the service center, provide accounting, payroll, human resources, information technology, legal, risk management, and other services to other operating subsidiaries through contractual relationships with such subsidiaries. In addition, our wholly owned captive insurance subsidiary, which we refer to as the insurance captive, provides certain claims made coverage to our operating companies for general and professional liability as well as for workers' compensation insurance liabilities. Enzyme also owns Standard Bear Healthcare REIT, Inc., which is a captive real estate investment trust that invests in healthcare properties and enters into lease agreements with certain independent subsidiaries of Enzyme, as well as third-party tenants that are unaffiliated with the Enzyme Group. The words Enzyme, company, we, our, and us refer to the Enzyme Group, Inc., and its consolidated subsidiaries. All of our operating subsidiaries, the service center, standard bearer healthcare REIT, and the insurance captive are operated by separate, wholly owned, independent companies that have their own management, employees, and assets. References herein to the consolidated company and its assets and activities, as well as the use of words we, us, our, and similar terms we may use today are not meant to imply, nor should it be construed as meaning, that the Enzyme Group has direct operating assets, employees, or revenue. or that any of the subsidiaries are operated by the Enzyme Group. Also, we supplement our gap reporting with non-gap metrics. When viewed together with our gap results, we believe that these measures can provide a more complete understanding of our business, but they should not be relied upon to the exclusion of gap reports. A gap to non-gap reconciliation is available in yesterday's press release and is available in our Form 10-Q. And with that, I'll turn the call over to Barry Port, our CEO. Barry?
spk07: Thanks, Chad, and thank you all for joining us today. We are proud to report another strong quarter and are pleased that we have been able to continue to improve our clinical and financial results across our portfolio. We are grateful for the efforts and commitment of our teams and caregivers and leaders who work endlessly to support and love one another, which allows for the high quality patient outcomes they consistently achieve. During the quarter, we saw continued improvement in occupancies and managed care revenues, which is particularly impressive given the persistent labor market pressures and the return of more typical seasonality. More specifically, we were pleased to see same-store occupancy of 79.5%, which grew by 290 basis points over the prior year quarter and by 97 basis points sequentially over the second quarter. Given the upward trend in same store occupancy through the quarter, we are confident that we are on a path to reach and eventually exceed our pre-COVID same store occupancy of 80.1% as we move into higher admission months of fall and winter. We also continue to build stronger relationships with our managed care partners due to better coordination of care, increased capabilities, and strong clinical outcomes. As a result, We saw increased volume in our same store in transitioning combined managed care census and managed care revenue, which increased during the quarter by 6.6% and 13.8%, respectively, over the prior year. As expected, we saw a seasonal decrease to skilled mix during the quarter. However, due to our local operators' strong clinical reputations, we are continuing to see elevated skilled mix when compared to pre-COVID levels. This continued growth and skilled mix demonstrates the increasing and sustainable demand for skilled post-acute services, including within the context of our managed care patients. We are very excited to see our local field and service center partners share and apply best practices as they respond to the persistent labor market challenges. As they instill our customer second culture into each operation, we have seen and will continue to see lower turnover. Likewise, we are also seeing less usage of third-party nursing agencies, which improved again for the ninth month in a row as of September, representing a reduction in agency usage of 55% since its peak in December of 2022. We are also encouraged to see wage inflation slow down and our ability to successfully recruit new talent grow. As of the end of the quarter, we saw our number of new hires increase by 69% since the end of March. Due to our solid results during the quarter, as well as continued strength from our recent acquisitions, we are increasing our annual 2023 earnings guidance to between $4.73 and $4.79 per diluted share, up from $4.70 to $4.78 per diluted share. This new midpoint of our 2023 earnings guidance represents an increase of 15% over our 2022 results, and is 30.8% higher than our 2021 results. We are also raising our annual revenue guidance to between 3.72 billion and 3.73 billion, up from our previous guidance of 3.69 billion to 3.73 billion. This increased guidance comes on top of the enormous growth we experienced in the last few years. To put this performance in perspective, Since we spun out the pennant group in 2019, we have seen adjusted EPS grow by 167% with a compound annual growth rate of 28%. This performance is not due to some large event or single transformative transaction, but instead is the result of consistent growth and performance quarter after quarter that comes from following proven and signed principles. We are excited about the upcoming year and are confident that our partners will continue to manage and innovate through all the lingering challenges on the labor front. In spite of our impressive results, we also recognize that there are many opportunities to improve on certain operational fundamentals, both in existing operations and the growing number of new acquisitions. As we evaluate our expanding portfolio, we see more organic growth potential within our existing portfolio than ever before. There are so many opportunities in front of us to improve labor and drive occupancy and skilled mix as we continue to successfully transition dozens of recently acquired operations. We also see enormous growth opportunities in skilled mix in a way that best serves each unique healthcare market. When combined with the number of very attractive acquisition opportunities that we see on the near and far horizon, we are poised to again showcase our ability to find, acquire, and transition performing and underperforming operations by applying proven in-time principles developed over two decades. As we relentlessly follow and protect the cultural fundamentals that got us here, we are confident that we will continue to consistently produce world-class clinical and financial performance. Next, I'll ask Chad to add some additional insights regarding our recent growth. Chad?
spk06: Thank you, Barry. As we expected, we continue to add to our growing portfolio and are very excited about the six new operations and four real estate assets we added during the quarter and since, bringing the number of operations in our newly acquired bucket to 51. These skilled nursing operations include two operations in South Carolina, one operation in Kansas, one operation in Colorado, and two operations in Washington. totaling an additional 621 new operational beds. We are excited to continue to grow in some of our most mature states, including Colorado and Washington, and to add an operation in Kansas that was formerly operated by a hospital. We are also thrilled to close on a transaction where Standard Bearer was able to acquire the real estate in Washington and lease a portion of the portfolio to a third-party tenant. We have seen many transactions similar to the one we closed in Washington that have been presented to us in the past and are anxious to utilize this new strategy to do more deals we likely would have missed out on prior to implementing this approach. All of these additions were carefully selected amongst the many opportunities we had and each of these were chosen because of the enormous clinical and financial potential in each operation. We have been patient and look forward to seeing our discipline pay off as these new operations continue to improve. As a result of skilled service expansion so far in 2023, occupancy and skilled mixed days for the skilled nursing operations in the newly acquired bucket was 77.4% and 26.1% respectively for the quarter. For those that have been following us for years will note, this is a very impressive starting point from which to build. However, when compared to our same store occupancy and skilled mixed days, of 79.5% and 30.7% respectively, there is enormous upside in each of these operations as they continue to transform into same store caliber operations. We are very optimistic about the organic growth potential within our existing portfolio as our new acquisitions are already contributing to our results, in many cases ahead of schedule. Looking forward, we have another busy fall and winter ahead of us and are preparing for even more growth in 2024. We continue to see a steady pipeline of new opportunities and are beginning to see the effects of higher interest rates on pricing, with more real estate opportunities coming to market at reasonable prices due to tighter financial markets. We also continue to see evidence that many operators are struggling, and as a result, we still expect there will be lots of opportunities that will arise. However, as we always remind you, we do not set arbitrary growth goals. and will remain true to our discipline acquisition strategy, only growing when we have the right leaders in place and the pricing is right. With our locally driven operating model, we have lots of operational bandwidth to grow across dozens of markets. We continue to provide additional disclosure on Standard Bear, which is now comprised of 107 properties owned by the company and leased to 78 affiliated skilled nursing and senior living operations, one campus operation to an unaffiliated tenant, and 29 senior living operations that are leased to the tenant group, Inc. Each of these properties is subject to a triple net long-term lease and generated rental revenue of $21 million for the quarter, of which $17 million was derived from Enzyme-affiliated operations. Also for the quarter, Standard Bear produced $13.6 million in FFO, and as of the end of the quarter had an EBITDAR to rent coverage ratio of 2.3 times. Looking forward, we are poised to grow with over a billion dollars in dry powder for future investments. But more importantly, our local leaders are constantly recruiting future CEOs of our operations, and we have a deep bench of CEOs in training that are eagerly preparing for their opportunity to lead. We look forward to actively seeking opportunities to acquire real estate and to lease both well-performing and struggling skilled nursing, senior living, and other healthcare-related businesses in our current footprint and in a few new states. And with that, I'll turn the call over to Spencer, our COO, to add more color around our operations. Spencer?
spk03: Thank you, Chad, and hello, everyone. As Barry highlighted, we have seen some exciting trends in occupancy, managed care growth, and cost containment, as well as continued progress in our recently acquired operations. For the next few minutes, I'd like to share highlights from two facilities to illustrate how local leaders are driving these improvements in spite of ongoing headwinds. The first example comes from Santa Rosa, California, one of the first facilities we ever acquired. Since joining the organization in the year 2000, Summerfield Healthcare Center has consistently achieved strong outcomes year after year, while also providing strength to sister facilities in the Northern California area. However, over the past year, COO and Director of Nursing, Enadina De La Cruz, and CEO, Kacen Bush, have taken performance to the next level. Compared to the prior year quarter, Summerfield's overall occupancy has increased by 7.5%, and skilled days have increased by 52.3%, with meaningful improvement in both Medicare and managed care payers. As a result, total net revenue has improved by 40%. while EBIT has soared by 126%, all while maintaining top-notch customer satisfaction and five-star CMS ratings in quality measures and overall. But the impact of Summerfield goes far beyond the performance of their facility. For example, when the North American transition occurred in February, three of these newly acquired facilities joined Summerfield's cluster. Leading up to the transition and since, Kaysen and Edina, as cluster leaders, have given countless hours of time and support to help their new partners acclimatize to the new culture and embrace the rigor of the cluster model. Results have followed. For example, despite initially having high agency in some of the newly acquired facilities, the entire cluster is now agency-free. At the same time, clinical systems have strengthened. Skilled mix has increased. and financial results have consistently improved. The second highlight demonstrates a similar story of highly competent leaders achieving great results in spite of challenges. Redmond Care and Rehabilitation is a five-star building located in Redmond, Washington. This amazing team, led by longtime CEO Nate Holmes and COO Debbie Dumondon, were one of the first facilities to confront COVID-19 when the pandemic emerged in Washington in early 2020. And like many of our strongest affiliates, the Redmond team found a way to turn the crucible of the past few years into clinical, cultural, and financial excellence that far exceeds their pre-pandemic performance. For example, by focusing on infection prevention and prioritizing their employees' well-beings, They have been able to recruit and develop some of the top clinical talent in the greater Seattle area during a time of intense staffing shortages. Strong recruiting, combined with turnover rates far below state and national averages, has in turn led to consistently exceptional clinical outcomes, such as a five-star CMS rating and some of the lowest hospitalization rates in the state. These outcomes in turn enhance relationships of trust with hospitals. and other healthcare continuum providers, which result in increased referrals. For example, Redmond grew overall occupancy by 9% and skilled days by 30% compared to Q3 of 2022. And as you would expect, revenues have soared by nearly 20%. The benefits of Redmond's Employee First formula extend far beyond just improved clinical reputation and occupancy. Redmond Care's emphasis on taking care of employees has actually led to a decrease in the cost of services because they aren't incurring expensive recruiting and onboarding costs, nor wasting money on high-priced agency staffing. Instead, the facility continues to invest in rewarding their own staff and increasing clinical competency, which will allow the impressive results to continue perpetually. We recognize there is still so much opportunity to improve in our operations. And having examples like Summerfield and Redmond gives us confidence that, as we are disciplined in applying tried and true principles, our future is bright. With that, I'll turn the time over to Suzanne to provide more detail on the company's financial performance and our guidance, and then we'll open it up for questions. Suzanne?
spk05: Thanks, Spencer, and good morning, everyone. Detailed financials for the quarter are contained in our TANQ and press release filed yesterday. Some additional highlights for the quarter include the following. Gap diluted earnings per share was $1.11, an increase of 12.1%. Adjusted diluted earnings per share was $1.20, an increase of 15.4%. Consolidated gap revenues and adjusted revenues were both $940.8 million, an increase of 22.2%. Gap net income was $63.9 million, an increase of 13.7%. and adjusted net income was $69 million, an increase of 16.6%. Other key metrics as of September 30th, 2023 include cash and cash equivalents of $467.9 million and cash flow from operations of $291.4 million. Currently, we have $593 million of available capacity under our revolving line of credit, which combined with the cash on our balance sheet give us over a billion dollars in dry powder for future investments. We also own 112 assets, of which 107 are held by Standard Bear, and 88 are owned completely debt-free and gaining significant value over time, adding even more liquidity to help us with future growth. During the quarter, we paid a quarterly cash dividend of 5.75 cents per share. We also continue to de-lever our portfolio. achieving a least adjusted net debt to EBITDA ratio of 1.99 times, which is particularly noteworthy given the amount of growth we have taken over the last year. As many of you know, CMS issued a proposed federal minimum staffing rule. We are now in the comment period and CMS has received and will continue to receive thousands of comments on the rule. However, if a final rule is implemented, we do not expect the rule to impact us in 2023 or 2024. We are encouraged by the strong reimbursement environment for Medicare and other payers. As of October 1st, we will receive a healthy net Medicare rate increase of 4%. In addition, most of the states we operate in have already adjusted their reimbursement to offset some of the reimbursement linked to the public health emergency that ended in May. For example, key states like Washington and Colorado announced encouraging increases to their rates. The combination of the rate environment and the slowing of inflation, some of our biggest costs, including labor, will continue to add to the operational momentum we have gained this year. As Barry mentioned, we are increasing our annual 2023 earnings guidance to between $4.73 to $4.79 per diluted share, up from $4.70 to $4.78 per diluted share. We are also raising our annual revenue guidance to between $3.72 and 3.73 billion. We have evaluated multiple scenarios and based on the strength in our performance and the positive momentum we have seen in occupancy and a strong skilled mix, as well as some additional strength in Medicaid and managed care programs, we are confident that we can meet this guidance. Our 2023 guidance is based on diluted weighted average common shares outstanding of approximately 57.7 million, a tax rate of 25%, the inclusion of acquisitions closed in 2023, the inclusion of management's expectations for Medicare and Medicaid reimbursement rates, net of provider tax, with the primary exclusions coming from stock-based compensation and certain expenses related to legal defense. Additionally, other factors that could impact quarterly performance include durations in reimbursement systems, delays and changes in state budgets, seasonality and occupancy in skilled mix, the influence of the general economy on census and staffing, the short-term impact of acquisition activities, variations in insurance accruals and other factors. And with that, I'll turn it back over to Barry. Barry?
spk07: Thanks, Suzanne. As we wrap up, I can't emphasize enough how incredibly honored and grateful we are to work alongside our facility leaders, field resources, clinical partners, and our service center team that are behind these record-setting results. We never cease to be amazed by the impressive resiliency as they focus on supporting one another in new and innovative ways. Their commitment has blessed the lives of so many, including our own, and we're excited about our future because of these amazing partners. We have complete faith in them and the culture they have collectively built. With that, we'll turn it now over to the Q&A portion of our call. Bailey, can you please instruct the audience on the Q&A procedure?
spk04: At this time, I would like to remind everyone in order to ask a question, press star and then the number one on your telephone keypad. Your first question comes from the line of Ben Hendricks with RBC Capital Markets. Your line is open.
spk01: Thank you very much. A quick M&A related question, and I think I've asked this on past calls, but wanted to get an update. Appreciate the commentary on the leadership development and price being kind of gating items for M&A, but wanted to get any thoughts on or any changes to strategy with regard to financing acquisitions amid the current rate environment, and if there's any kind of capital allocation considerations from that perspective. Thanks.
spk06: Yeah, great question, Ben. Thanks for that. As we mentioned in the call, we have over a billion dollars in dry powder. A good portion of that is cash. So we've got a lot of cash. And then our revolver has been completely, it's just totally available to us. So usually what we do is it's some kind of a blend between the two. And our debt levels are extremely low. And frankly, our overall sort of cost of capital is attractive. It's, you know, SOFR-based with a spread to it that I think is very, very competitive and certainly puts us in a spot that is enviable amongst many financial buyers in particular. So pretty excited about, you know, the ability we have both with cash and, you know, to use our revolver to fund it. Obviously, we have a lot of real estate that we own that's completely unlevered as well. Doing mortgage financings is something that we've done in the past. Given current rates, though, that's probably not on the horizon, at least in the near term.
spk08: Thank you.
spk04: Your next question comes from the line of Scott Fidel with Stevens. Your line is open.
spk02: Hi, thanks. I actually wanted to just follow up on the same topic as Ben just talked about with the M&A opportunity and just given the extensive capital available to you. Just interested if maybe you could drill into the profile of deals looking out to 2024 that may be available when thinking about the larger portfolio deal you did with North American this year and I guess what the pipeline of, you know, sort of other portfolio opportunities may look like as compared to, you know, some of the more targeted deals that you often also do during the course of the year.
spk06: Yeah, great question, Scott. So, you know, first of all, you know, the onesies, twosies, the deals that have really built Enzyme, those are, there's lots of them. So that's kind of, I guess, our typical pattern, and we expect to follow that. But in terms of portfolio deals, we have seen, even just in the last couple months, an uptick in the number of larger deals that are out there. It's an interesting mix. Some include real estate that would require an actual cash payment. Others are more lease-heavy. And as we've shown, we prefer to buy the real estate where we can, but really attractive leases are a great way for us to grow as well. I would say really all the portfolios that we've seen and the sizable ones are very much distressed and in a turnaround situation. That is a little bit different than the North American deal we did last year. you know, was unique for sure in terms of occupancy and, you know, California-based. So, but all that said, you know, the biggest factor, as was alluded to earlier, is the leadership and having leaders in our pipeline that are waiting for those opportunities. And obviously, geography is important as well. We want to stay, you know, in the states we're in is sort of our first priority. simply because there's a lot of benefit in building scale in the same markets. We know them. There's a lot of benefit in having relationships with hospital systems and managed care payers and all of that. So that's our very first priority is to grow in the states we're in. And some of these opportunities are in states we're in. The next one would be states that we're not in but that are close by. So there are a few new states that could potentially happen either at the end of this year or early next. We take those very seriously. It's a lot of work to go into a new state, but that's definitely something on the horizon as well. Anything I missed, Suzanne or Barry?
spk02: No, not at all. Okay, great. Thanks, Chad. And then a follow-up question, just wanted to pivot over to the the staffing rule, and I guess just ask a question about sort of I guess how you're approaching this, you know, from the advocacy versus the operational perspective. I think everyone recognizes how disruptive this proposal would be for the industry if it went forward, and it seems realistic to think that there will be some meaningful changes made in the final rule. But, you know, at the same time, we may not even see that until next summer or so. So, I'm just curious, you know, are you at this point largely just focusing your efforts on sort of the advocacy side? Or are you, you know, also considering any types of, you know, starting to pursue operational adjustments, you know, looking out, you know, over a multi-year timeframe that this rule would go into effect?
spk07: Yeah, it's a great question. Scott, operationally, I don't think there's much that we feel like we need to do to adjust other than making sure we're really, really focused on the things that we're always focused on, which are keeping turnover as low as we can by making sure we've just got amazing practices around how We treat and incentivize and celebrate our people, making sure that we're the employer of choice in every market, making sure that we're very efficient in how we staff and the communication we have with our staff on how and why we're staffing a certain way, and getting their input on that as well. So, you know, that has been our focus for quite some time, you know, removing agency and ensuring that, you know, the workplace is a place where people really want to be. That really is our focus because if and when there is some adjustment to how the federal government decides we should staff on a building by building basis, if our people systems aren't where they ought to be, then that becomes more challenging. So our efforts operationally are around making sure that we continue to be the absolute best employer we can be. So the silver lining of this whole noise around this proposed rule is that it gives us impetus and a rally cry to kind of focus on making sure that we're the best. being great partners with our employees. As it relates to what we're doing organizationally, it really is very much a grassroots kind of focus. So we're in a heavy comment period right now. It ends November 6th. Our organization has produced well over 1,000 comments. The industry has produced over 11,000 comments. Congress just recently had a Nearly 100 congresspeople sent a letter that they signed. So we're even getting comments from lawmakers. And now our efforts really are focused on, as an industry, making sure that we're in the offices and in front of legislators that can have influence over this. And really, the ultimate goal there isn't necessarily to fight it, although you see some legislation that's been proposed. And given the continuing resolution around the budget, there is a window and potentially an opportunity to have that legislation somehow make its way into a voting situation. But that's an outside chance. Really, our focus is really on shaping the rule at this point. I think it would be a futile effort to rally too much energy around getting it just completely struck down. There really is, because it's so White House and union driven, there's far too much support for that to essentially be, you know, a real possibility. So our goal and our focus is to shape it and make it something that really that we can all live with and make some sense. and then potentially set that up for a legal challenge down the road. And, you know, again, that's something you deal with after the fact. But, you know, again, our focus is on shaping it rather than trying to do anything less productive.
spk02: Thanks. I appreciate those comments. If I could just put one more question in, too, for you. Just I know there's a Medicaid rebasing process that's underway, I think, in California. Would appreciate maybe if you could just bring us up to speed on sort of what exactly is going on there and sort of what you'd be looking for out of that process underway. Thanks a lot.
spk05: Yeah, great question, Scott. Definitely a lot of things happening in California with regards to the Medicaid rate. We're very, very, very active. with both our association, lobbyists in California, and the department in shaping what that will ultimately look like. And so we continue to be very active in that and be a part of those discussions.
spk07: As far as the, you know, any rebasing, I don't, I don't, we really don't feel like there's any overarching threat to you know, the population that we serve, it's more community-based Medicaid patients that are being redetermined. And, you know, I know there's some questions about the redetermination process on Medicaid in some states, and you've asked about that before, too, which is separate from what you asked Suzanne about. That piece, too, is something that, you know, is really not much of a threat to to what we're seeing in our facilities as far as our patient population, other than it's just creating a slowdown in terms of getting Medicaid patients approved.
spk08: Okay, great. Thank you.
spk04: There are no further questions at this time. Mr. Port, I will turn the call back over to you.
spk07: Okay, thanks, Bailey, and thanks, everyone, for joining us today. We appreciate, obviously, your support and look forward to a strong finish to the year.
spk04: This concludes today's conference call. You may now disconnect.
Disclaimer